I would like to start by introducing four of my patients who are on treatment in our hospital’s peritoneal dialysis unit. Mrs A.M. is a 91-year-old lady, an ex-professor of arts at the University of Toronto, who, on the days off dialysis, lives by herself in her home and is cared for by her neighbours. Mrs M. T. is a 65-year-old blind diabetic patient with both legs amputated,who would not be accepted by any chronic care hospital; on her days off dialysis she lives with one of her five daughters. Mrs H. is a 69-year-old woman with systemic amyloidosis, bilateral hip arthritis requiring hip replacement, severe heart disease requiring a pacemaker and incapacitating back pain. Finally, Mrs. K. is a 76-year-old patient with severe heart and respiratory failure that prevents her from moving.
KeywordsGross National Product Worth Living Systemic Amyloidosis Global Budget Artificial Kidney
Unable to display preview. Download preview PDF.
- Friedman, E. A. and Delano, B. G. (1981). Can the world afford uremia therapy? In Zurukzoglu, W.M., Papadimitriou, M., Pyrpasopoulos, M., Sion, C. and Zamboulis, C. (eds.) Proceedings 8th International Congress of Nephrology, pp. 577–583 ( Basel: Karger )Google Scholar
- Galetti, P.M. (1979). Organ replacement technology: its impact on the quality and cost of medical care. Frank W. Hastings lecture. NIH contractors meeting, Devices and Technology Branch, December 10–12Google Scholar